Please login to the form below

Not currently logged in
Email:
Password:

GSK fails to find global buyer for OTC brand portfolio

Does £426m deal with Prestige Brands Holding for some US and Canada rights

GlaxoSmithKline (GSK) has sold the rights to several 'non-core' over-the-counter (OTC) products in the US and Canada to Prestige Brands Holdings for £426m.

The US-based company, which markets, sells and distributes OTC and household cleaning products to retail outlets, acquires the rights to the brands such as GSK's aspirin Ecotrin, pain reliever BC and heartburn treatment Tagamet.

GSK had originally intended to agree a single global deal for all the OTC products, including its weight loss treatment Alli, with US private equity firm Thomas H Lee Partners (THL) seen as the lead candidate.

So it still needs a European buyer for the products, and global rights to Alli remain on the table. Negotiations for these product licences, which GSK said brought in revenues of around £400m during 2010, remain ongoing.

Simon Dingemans, GSK's chief financial officer, said: "The disposal of our non-core consumer brands is about realising attractive value for shareholders as well as simplifying our ongoing consumer business and allowing it to focus on its priority brands and markets.”

The products acquired by Prestige Brands Holdings brought in £134m during 2010 and £98m in the first nine months of 2011.

GSK originally announced its intention to sell off the OTC products in April, 2011, claiming the lines lacked 'sufficient critical mass'.

It defined the three priorities of its consumer healthcare business as oral health, wellness/OTC and Nutrition, citing such products as Sensodyne and Panodol as its priority brands.

Andrew Witty, CEO of GSK, described its consumer business as a “key growth driver” but said the company had to focus on products with the “best prospects” for growth.

21st December 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....